Intas Pharmaceuticals has appointed Arun R Hegde as Vice President of Sales & Marketing for its Oncology division. With over 30 years in the biopharmaceutical industry, Arun brings extensive experience in launching and managing innovative cancer treatments. Notably, he played a key role in the launch of Keytruda (Pembrolizumab), India’s first immuno-oncology drug, along with biosimilar monoclonal antibodies like Hertraz (Trastuzumab) and Reditux (Rituximab). His expertise spans crucial therapeutic areas, including Immuno-Oncology and Haemato-Oncology, where he developed strategies to improve patient access to critical medicines.
Before joining Intas, Arun held senior leadership roles at MSD Pharmaceuticals and Mylan, contributing significantly to the launch and establishment of several major oncology and biosimilar products. Known for his collaborative approach with both internal teams and external stakeholders, he has been instrumental in driving business growth and enhancing healthcare accessibility. At Intas, Arun will lead the oncology division with a focus on strategic expansion, broadening the product portfolio, and ensuring that more patients benefit from advanced cancer treatments.
